Roflumilast Foam Looks Promising in Seborrheic Dermatitis Trial
Roflumilast is a highly potent and selective phosphodiesterase type 4 inhibitor.
Dermatitis
Abrocitinib After Dupilumab in Adults With Atopic Dermatitis
Researchers sought to evaluate results from adults with moderate to severe atopic dermatitis who are treated with abrocitinib after being treated with dupilumab.
Improvements in Skin Clearance Maintained With Lebrikizumab in Atopic Dermatitis Trials
The ADvocate 1 and ADvocate 2 trials evaluated lebrikizumab as monotherapy in patients aged 12 years and older weighing at least 40kg with moderate to severe atopic dermatitis.
Hormone Levels and Asthma, Rhinitis, and Eczema
Important clinical considerations for clinicians treating asthma, rhinitis, and atopic dermatitis are presented.
10 Days’ Minimum for Best ROAT Results
The ideal duration for obtaining a positive repeated open application test (ROAT) for a topical product is investigated.
Acne Risk and Severity in Patients With AD Varies By Age and Sex
The prevalence, incidence, and risk for acne in adolescent and adult patients with atopic dermatitis (AD) is assessed.
Real-World Success of Dupilumab for Treating Atopic Dermatitis in Adolescents
A real-world study on the safety and efficacy of dupilumab as a treatment for atopic dermatitis in adolescents was conducted.
Lotion, Cream, Gel, and Ointment Similarly Effective for Childhood Eczema
There are no differences in effectiveness between the four main types of moisturizers for childhood eczema.
Sodium Intake Linked to Risk for Atopic Dermatitis
Increased consumption of dietary sodium may increase the risk for atopic dermatitis.
Ruxolitinib Cream Promising for Maximum-Use in Atopic Dermatitis
The safety and tolerability of ruxolitinib cream 1.5% for maximum-use in patients with atopic dermatitis is investigated.
- Loading...
Loading...
Next post in Dermatitis
Loading... 
Loading...